CASE REPORT

Minimally invasive left atrial appendage (LAA) clip insertion after challenging LAA occluder implantation to minimize the risk of stroke

Ayse Cetinkaya1,*, Mohamed Zeriouh1, Oliver-Joannis Liakopoulos1, Stefan Hein1, Tamo Siemons2, Peter Bramlage3, Markus Schönburg1, Yeong-Hoon Choi1 and Manfred Richter1

1Department of Cardiac Surgery, Kerckhoff-Heart Center, Bad Nauheim, Germany, 2Department of Radiology, Kerckhoff-Heart Center, Bad Nauheim, Germany and 3Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany

*Correspondence address. Department of Cardiac Surgery, Kerckhoff-Heart Center Bad Nauheim, Benekestraße 2-8, 623231 Bad Nauheim, Germany. Tel: +49 6032 996 2502; Fax: +49 6032 996 2567; E-mail: a.cetinkaya@kerckhoff-klinik.de

Abstract

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, requiring lifelong anticoagulation or interventional, transseptal left atrial appendage (LAA) occluder implantation to minimize stroke risk. Incomplete LAA closure post implantation is a frequent observation. Incomplete LAA occlusion after transseptal occluder implantation necessitates anticoagulation in cases of persistent AF to minimize risk of embolism and/or apoplexy. Patients with contraindications to lifelong anticoagulation therapy are challenging to treat and alternative options are needed. We present a case of a patient with persistent AF who underwent frustraneous LAA occluder implantation. The patient’s anatomy necessitated surgical closure of the LAA, which was accomplished with an LAA clip 4 weeks after implantation. The patient was discharged in excellent clinical status 5 days after the surgery. No further complications were observed within the following year.

INTRODUCTION

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and a major risk factor for stroke [1–3]. Gold-standard stroke prevention is lifelong anticoagulation, which is not suitable for all patients [3, 4]. Overall, 90% and 57% of thrombi found in non-valvular and valvular AF patients, respectively, are in the LAA, making it a target for stroke prevention [3]. LAA occlusion devices are a mechanical alternative to oral anticoagulation [4, 5]. Cases of challenging primary transseptal LAA occluder implantations have been reported, particularly in patients with certain types of LAA anatomy [6], which can result in small peri-device leaks and increase thromboembolism risk [7]. We report on a patient with frustraneous LAA occluder implantation and complete LAA closure.
CASE REPORT

Patient history

A 63-year-old patient presented with persistent AF. On hospital admission, the patient was in good condition, with a body mass index of 24 kg/m². Patient history revealed that 15 years previously they suffered a cerebral haemorrhage and recovered without evidence of residual lesions. A routine examination 3 years ago, identified persistent AF with a CHADS-VASc score of 2 (hypertension +1, stroke +1). Ejection fraction was normal (55%). The patient was on 2.5 mg bisoprolol twice daily for rate control. Treatment (20 mg rivaroxaban pod) was initiated. The patient suffered recurrent cerebral bleeding ~3 months ago; anticoagulant treatment was stopped.

LAA occluder implantation

A treatment review for AF was undertaken, but no further action such as MAZE, pulmonary vein isolation, electrophysiology intervention or rhythm control were considered viable strategies. An LAA occluder implantation (Amplatzer Amulet LAA Occluder, Abbott) was carried out under transoesophageal echocardiography (TEE)-guidance and general anaesthesia (Figs 1 and 2). The left atrium was accessed via the right femoral vein (7F 8.5F sheath). The transseptal puncture with an SL1 catheter was changed to the SL1. The Amplatzer Amulet 16/20/25 mm LAA occluder implantation remained challenging due to the unusual anatomy with an atypical position of the auricular appendage. Finally the procedure was aborted in favour of a LAA clip.

During the procedure and subsequent telemetric monitoring, recurrent bradycardia and sinoatrial block with pauses of ~5 s was noticed. Asymptomatic left atrial tachycardia with heart rate ~150/min occurred. The patient was diagnosed with sick sinus syndrome, but remained asymptomatic during arrhythmias. The presence of tachycardia-bradycardia syndrome was an indication for pacemaker implantation and a DDD pacemaker (Assurity DR MRI, Abbott) was implanted 1 week later and showed appropriate aggregate function.

LAA clipping

Surgical implantation of an LAA clip using a minimally invasive technique was discussed. Fondaparinux (2.5 mg once daily) was initiated due to CHA2DS2-VASc score of 2 and increased HAS-BLED score after two bleeding episodes. After ~4 weeks, the patient was admitted to our department.

A cardiac computed tomography excluded coronary heart disease and showed the LAA was raised anteriorly at the level of the left upper pulmonary vein and had a chicken-wing shape, with an anterior curvature to the right (Fig. 3). Ectasia of the ascending aorta (41 × 41 mm at pulmonary artery level) was detected.

An LAA clip was implanted, under general anaesthesia with a double lumen tube, via a left mini-thoracotomy without a heart-lung machine. Briefly, a 7 cm skin incision was made laterally above the left mamilla (Fig. 4). Preparation of the subcutis and pectoralis muscle in the fourth intercostal space exposed the LAA. The LAA clip (AtriCure 40 mm) was placed over the LAA to its base. Transoesophageal echocardiography was used to complete LAA closure, the clip was closed and holding device removed (Fig. 5). The patient received 2.5 mg fondaparinux once daily to prevent thrombosis formation; once mobile anticoagulation was stopped. Five days post intervention, the patient was discharged in good clinical condition. Wound healing was uneventful at 10 days. After 1 year without anticoagulation, no further complications were observed.

DISCUSSION

AF is a risk factor for stroke and necessitates either pharmacological intervention or mechanical intervention with implantation of an LAA occluder device [3]. Interventional LAA closure via transseptal puncture for LAA occluder implantation is a standard therapy, but is challenging in patients with certain morphologies/large LAA [6]. The safety and effectiveness of LAA occluder implantation in patients with non-valvular AF is established [4, 8], but can be associated with incomplete LAA closure [7, 9]. LAA anatomy can complicate implantation, potentially contributing to incomplete occlusion/increasing thrombosis risk [10]. We show that minimally invasive LAA clip implantation via left lateral mini thoracotomy is safe and effective for LAA closure.
Minimally invasive LAA clip insertion

Figure 2: TEE for interventional LAA occluder implantation, TEE controlled, unsuccessful LAA occluder implantation due to difficult LAA morphology.

Figure 3: Preoperative cardiac computed tomography (CT) ‘Chicken wing’ morphology of the LAA; cardio CT for presentation of the special (Chicken wing morphology) of the LAA and for exclusion of coronary heart disease before surgical LAA clip implantation.

Figure 4: Intraoperative photographs: set-up and LAA clip; intraoperative setup and intra-thoracic images of the LAA clip positioning/implantation.
Figure 5: Transoesophageal echocardiography control of the LAA clip in correct position at the LAA base with display of the complete LAA closure.

CONFLICT OF INTEREST STATEMENT
None declared.

FUNDING
None.

REFERENCES
1. Wyndham CR. Atrial fibrillation: the most common arrhythmia. Tex Heart Inst J 2000;27:257–67.
2. Davis RC, Hobbs FD, Kenkre JE, Roalfe AK, Iles R, Lip GY, et al. Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. Europace 2012;14:1553–9.
3. Ramlawi B, Abu Saleh WK, Edgerton J. The left atrial appendage: target for stroke reduction in atrial fibrillation. Methodist Debakey Cardiovasc J 2015;11:100–3.
4. Moussa Pacha H, Al-Khadra Y, Soud M, Darmoch F, Moussa Pacha A, Alraies MC. Percutaneous devices for left atrial appendage occlusion: a contemporary review. World J Cardiol 2019;11:57–70.
5. Couch G, Sabir I. The WATCHMAN device for stroke prophylaxis in atrial fibrillation: an evolving niche. Hosp Pract (1995) 2015;43:13–21.
6. Dieker W, Behnes M, Fastner C, Sartorius B, Wenke A, Sing-Gill I, et al. Impact of left atrial appendage morphology on thrombus formation after successful left atrial appendage occlusion: assessment with cardiac-computed-tomography. Sci Rep 2018;8:1670.
7. Viles-Gonzalez JF, Kar S, Douglas P, Dukkipati S, Feldman T, Horton R, et al. The clinical impact of incomplete left atrial appendage closure with the Watchman device in patients with atrial fibrillation: a PROTECT AF (percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation) substudy. J Am Coll Cardiol 2012;59:923–9.
8. Majule DN, Jing C, Rutahoile WM, Shonyela FS. The efficacy and safety of the WATCHMAN device in LAA occlusion in patients with non-valvular atrial fibrillation contraindicated to oral anticoagulation: a focused review. Ann Thorac Cardiovasc Surg 2018;24:271–8.
9. Lam SC, Bertog S, Sievert H. Incomplete left atrial appendage occlusion and thrombus formation after Watchman implantation treated with anticoagulation followed by further transcatheter closure with a second-generation Amplatzer cardiac plug (amulet device). Catheter Cardiovasc Interv 2015;85:321–7.
10. Akin I, Nienaber CA. Left atrial appendage occlusion: a better alternative to anticoagulation? World J Cardiol 2017;9:139–46.